Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?
Open Access
- 1 January 2023
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 15
Abstract
The management of locally advanced rectal cancer (LARC) requires multimodality treatment, typically with neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision. However, the treatment landscape is rapidly evolving with total neoadjuvant therapy and non-operative management for selected patients emerging as other novel treatment approaches. With so many treatment options, there is a need for biomarkers to direct a more personalised treatment strategy for patients with LARC. In this review, we summarise the available data regarding the use of circulating tumour DNA (ctDNA) in patients with LARC, as both a marker of treatment response to neoadjuvant therapy and as a marker of minimal residual disease (MRD) after patients have completed definitive local treatment. To date, the ability of ctDNA status to predict for pathologic complete response at any timepoint during multimodality treatment has been variably reported. The most consistent finding across available studies is the ability of ctDNA to detect MRD after CRT and surgery, the presence of which confers a significantly poor prognosis, with increased risk of cancer recurrence and worse overall survival. It is yet to be determined if providing additional therapies to patients with MRD improves outcomes. The available studies assessing the potential utility of ctDNA in LARC are limited by significant heterogeneity in the choice of ctDNA assay, timepoint at which ctDNA was collected, treatment that patients received and length of follow-up, leading to uncertainties about how to implement it into daily clinical practice. As the treatment landscape evolves, larger randomised trials assessing the role of ctDNA in LARC are needed.Keywords
This publication has 41 references indexed in Scilit:
- Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant TherapyAnnals of Surgery, 2012
- Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation DosesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)Journal of Clinical Oncology, 2012
- Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database of Systematic Reviews, 2012
- Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancerBritish Journal of Surgery, 2012
- Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal CancerJournal of Clinical Oncology, 2011
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2010
- Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal CancerAnnals of Surgical Oncology, 2010
- Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation TherapyAnnals of Surgery, 2004
- Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 PatientsJournal of the American College of Surgeons, 2002